{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:21:33Z","timestamp":1792707693505,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471199"],"award-info":[{"award-number":["82471199"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171582"],"award-info":[{"award-number":["82171582"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00415-026-13726-z","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:13:53Z","timestamp":1772709233000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Plasma p-tau217 assays effectively predict amyloid status but lack precision for tau staging in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"273","author":[{"given":"Yuhan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,5]]},"reference":[{"issue":"7","key":"13726_CR1","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","volume":"20","author":"SE Schindler","year":"2024","unstructured":"Schindler SE et al (2024) Acceptable performance of blood biomarker tests of amyloid pathology \u2014 recommendations from the Global CEO Initiative on Alzheimer\u2019s Disease. Nat Rev Neurol 20(7):426\u2013439","journal-title":"Nat Rev Neurol"},{"issue":"8","key":"13726_CR2","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimer\u2019s Dementia 20(8):5143\u20135169","journal-title":"Alzheimer's Dementia"},{"key":"13726_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barth\u00e9lemy","year":"2024","unstructured":"Barth\u00e9lemy NR et al (2024) Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med 30:1085\u20131095","journal-title":"Nat Med"},{"key":"13726_CR4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton NJ et al (2024) Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for alzheimer disease pathology. JAMA Neurol 81:255\u2013263","journal-title":"JAMA Neurol"},{"key":"13726_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19:422\u2013433","journal-title":"Lancet Neurol"},{"key":"13726_CR6","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/alz.12724","volume":"19","author":"P Chatterjee","year":"2023","unstructured":"Chatterjee P et al (2023) Plasma A\u03b242\/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer\u2019s disease continuum: a cross-sectional and longitudinal study in the AIBL cohort. Alzheimers Dement 19:1117\u20131134","journal-title":"Alzheimers Dement"},{"key":"13726_CR7","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet AL et al (2021) Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol 78:1471\u20131483","journal-title":"JAMA Neurol"},{"key":"13726_CR8","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1093\/brain\/awac333","volume":"146","author":"S Janelidze","year":"2022","unstructured":"Janelidze S et al (2022) Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain 146:1592\u20131601","journal-title":"Brain"},{"key":"13726_CR9","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamaneurol.2021.3180","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S et al (2021) Head-to-head comparison of 8 plasma amyloid-\u03b2 42\/40 assays in Alzheimer disease. JAMA Neurol 78:1375\u20131382","journal-title":"JAMA Neurol"},{"key":"13726_CR10","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/alz.12841","volume":"19","author":"NJ Ashton","year":"2023","unstructured":"Ashton NJ et al (2023) Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays. Alzheimers Dement 19:1913\u20131924","journal-title":"Alzheimers Dement"},{"key":"13726_CR11","doi-asserted-by":"publisher","first-page":"105046","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J et al (2024) Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine 102:105046","journal-title":"EBioMedicine"},{"key":"13726_CR12","doi-asserted-by":"crossref","unstructured":"Warmenhoven N, et al. A Comprehensive Head-to-Head Comparison of Key Plasma Phosphorylated Tau 217 Biomarker Tests. medRxiv, 2024.2007.2002.24309629 (2024).","DOI":"10.1101\/2024.07.02.24309629"},{"key":"13726_CR13","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1093\/brain\/awad042","volume":"146","author":"CR Jack Jr","year":"2023","unstructured":"Jack CR Jr et al (2023) Predicting amyloid PET and tau PET stages with plasma biomarkers. Brain 146:2029\u20132044","journal-title":"Brain"},{"key":"13726_CR14","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1002\/alz.13764","volume":"20","author":"MR Meyer","year":"2024","unstructured":"Meyer MR et al (2024) Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and A\u03b242\/40 ratio to identify presence of brain amyloid. Alzheimers Dement 20:3179\u20133192","journal-title":"Alzheimers Dement"},{"key":"13726_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42596-6","volume":"14","author":"H Cai","year":"2023","unstructured":"Cai H, Pang Y, Fu X, Ren Z, Jia L (2023) Plasma biomarkers predict Alzheimer\u2019s disease before clinical onset in Chinese cohorts. Nat Commun 14:6747","journal-title":"Nat Commun"},{"key":"13726_CR16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Sch\u00f6ll","year":"2016","unstructured":"Sch\u00f6ll M et al (2016) PET imaging of tau deposition in the aging human brain. Neuron 89:971\u2013982","journal-title":"Neuron"},{"key":"13726_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2018.12917","volume":"320","author":"R Ossenkoppele","year":"2018","unstructured":"Ossenkoppele R et al (2018) Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA 320:1151\u20131162","journal-title":"JAMA"},{"key":"13726_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CHV Dyck","year":"2023","unstructured":"Dyck CHV et al (2023) Lecanemab in early Alzheimer\u2019s disease. New Eng J Med 388:9\u201321","journal-title":"New Eng J Med"},{"key":"13726_CR19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1056\/NEJMc2314291","volume":"390","author":"RJ Bateman","year":"2024","unstructured":"Bateman RJ, Smith J, Doody RS (2024) Gantenerumab in early Alzheimer\u2019s Disease. N Engl J Med 390:866\u2013867","journal-title":"N Engl J Med"},{"key":"13726_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR et al (2023) Donanemab in early symptomatic alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical Trial. JAMA 330:512\u2013527","journal-title":"JAMA"},{"key":"13726_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","volume":"81","author":"N Mattsson-Carlgren","year":"2024","unstructured":"Mattsson-Carlgren N et al (2024) Plasma biomarker strategy for selecting patients with Alzheimer disease for antiamyloid immunotherapies. JAMA Neurol 81:69\u201378","journal-title":"JAMA Neurol"},{"key":"13726_CR22","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1038\/s41380-020-00950-w","volume":"26","author":"A Sala","year":"2021","unstructured":"Sala A, Nordberg A, Rodriguez-Vieitez E (2021) Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-\u03b2 positivity. Mol Psychiatry 26:5864\u20135874","journal-title":"Mol Psychiatry"},{"key":"13726_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209419","volume":"103","author":"SE Mastenbroek","year":"2024","unstructured":"Mastenbroek SE et al (2024) Continuous \u03b2-amyloid CSF\/PET imbalance model to capture Alzheimer disease heterogeneity. Neurology 103:e209419","journal-title":"Neurology"},{"key":"13726_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J et al (2023) Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. JAMA Neurol 80:188\u2013199","journal-title":"JAMA Neurol"},{"key":"13726_CR25","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1093\/brain\/awae346","volume":"148","author":"N Warmenhoven","year":"2025","unstructured":"Warmenhoven N et al (2025) A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain 148:416\u2013431","journal-title":"Brain"},{"key":"13726_CR26","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1212\/WNL.0b013e3181cb3e25","volume":"74","author":"RC Petersen","year":"2010","unstructured":"Petersen RC et al (2010) Alzheimer\u2019s Disease Neuroimaging Initiative (ADNI). Neurology 74:201\u2013209","journal-title":"Neurology"},{"key":"13726_CR27","unstructured":"Schindler, S.E., et al. Head-to-head comparison of leading blood tests for Alzheimer\u2019s disease pathology. medRxiv, 2024.2006.2012.24308839 (2024)."},{"key":"13726_CR28","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA et al (2023) Trial of solanezumab in preclinical Alzheimer\u2019s Disease. N Engl J Med 389:1096\u20131107","journal-title":"N Engl J Med"},{"key":"13726_CR29","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaneurol.2020.0387","volume":"77","author":"RA Sperling","year":"2020","unstructured":"Sperling RA et al (2020) Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol 77:735\u2013745","journal-title":"JAMA Neurol"},{"key":"13726_CR30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s13195-021-00836-1","volume":"13","author":"SK Royse","year":"2021","unstructured":"Royse SK et al (2021) Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach. Alzheimer\u2019s Res Ther 13:99","journal-title":"Alzheimer's Res Ther"},{"key":"13726_CR31","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.neuroimage.2017.05.058","volume":"157","author":"A Maass","year":"2017","unstructured":"Maass A et al (2017) Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer\u2019s disease. Neuroimage 157:448\u2013463","journal-title":"Neuroimage"},{"key":"13726_CR32","doi-asserted-by":"crossref","unstructured":"Jagust, W.J., et al. The ADNI PET Core at 20. Alzheimer's & Dementia n\/a.","DOI":"10.1002\/alz.14165"},{"key":"13726_CR33","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/brain\/awac299","volume":"146","author":"PS Insel","year":"2022","unstructured":"Insel PS et al (2022) Tau positron emission tomography in preclinical Alzheimer\u2019s disease. Brain 146:700\u2013711","journal-title":"Brain"},{"key":"13726_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41467-019-14159-1","volume":"11","author":"N Franzmeier","year":"2020","unstructured":"Franzmeier N et al (2020) Functional brain architecture is associated with the rate of tau accumulation in Alzheimer\u2019s disease. Nat Commun 11:347","journal-title":"Nat Commun"},{"key":"13726_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00880-x","volume":"13","author":"D Biel","year":"2021","unstructured":"Biel D et al (2021) Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals. Alzheimers Res Ther 13:137","journal-title":"Alzheimers Res Ther"},{"key":"13726_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2014.07.003","volume":"11","author":"WE Klunk","year":"2015","unstructured":"Klunk WE et al (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:1-15.e14","journal-title":"Alzheimers Dement"},{"key":"13726_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00590-4","volume":"18","author":"CB Young","year":"2023","unstructured":"Young CB et al (2023) APOE effects on regional tau in preclinical Alzheimer\u2019s disease. Mol Neurodegener 18:1","journal-title":"Mol Neurodegener"},{"key":"13726_CR38","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/alz.12422","volume":"18","author":"DP Veitch","year":"2022","unstructured":"Veitch DP et al (2022) Using the Alzheimer\u2019s Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer\u2019s disease. Alzheimers Dement 18:824\u2013857","journal-title":"Alzheimers Dement"},{"key":"13726_CR39","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1002\/alz.13393","volume":"19","author":"PCL Ferreira","year":"2023","unstructured":"Ferreira PCL et al (2023) Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals. Alzheimers Dement 19:4463\u20134474","journal-title":"Alzheimers Dement"},{"key":"13726_CR40","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324:772\u2013781","journal-title":"JAMA"},{"key":"13726_CR41","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrn.2015.1","volume":"17","author":"Y Wang","year":"2016","unstructured":"Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17:5\u201321","journal-title":"Nat Rev Neurosci"},{"key":"13726_CR42","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.bbadis.2004.09.008","volume":"1739","author":"K Iqbal","year":"2005","unstructured":"Iqbal K et al (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739:198\u2013210","journal-title":"Biochim Biophys Acta"},{"key":"13726_CR43","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barth\u00e9lemy","year":"2023","unstructured":"Barth\u00e9lemy NR et al (2023) CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nature Aging 3:391\u2013401","journal-title":"Nature Aging"},{"key":"13726_CR44","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1002\/alz.13413","volume":"19","author":"Z-B Wang","year":"2023","unstructured":"Wang Z-B et al (2023) Associations of the A\/T\/N profiles in PET, CSF, and plasma biomarkers with Alzheimer\u2019s disease neuropathology at autopsy. Alzheimers Dement 19:4421\u20134435","journal-title":"Alzheimers Dement"},{"issue":"9","key":"13726_CR45","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","volume":"81","author":"S Janelidze","year":"2024","unstructured":"Janelidze S et al (2024) Plasma Phosphorylated Tau 217 and A\u03b242\/40 to Predict Early Brain A\u03b2 Accumulation in People Without Cognitive Impairment. JAMA Neurol 81(9):947\u2013957","journal-title":"JAMA Neurol"},{"key":"13726_CR46","doi-asserted-by":"publisher","first-page":"e1580","DOI":"10.1212\/WNL.0000000000009240","volume":"94","author":"JD Doecke","year":"2020","unstructured":"Doecke JD et al (2020) Total A\u03b242\/A\u03b240 ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology 94:e1580\u2013e1591","journal-title":"Neurology"},{"key":"13726_CR47","doi-asserted-by":"publisher","first-page":"3505","DOI":"10.1093\/brain\/awab223","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB et al (2021) Plasma GFAP is an early marker of amyloid-\u03b2 but not tau pathology in Alzheimer\u2019s disease. Brain 144:3505\u20133516","journal-title":"Brain"},{"key":"13726_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-024-00707-x","volume":"19","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez J et al (2024) Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer\u2019s Disease. Mol Neurodegener 19:19","journal-title":"Mol Neurodegener"},{"key":"13726_CR49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00401-022-02408-5","volume":"143","author":"DS Smirnov","year":"2022","unstructured":"Smirnov DS et al (2022) Plasma biomarkers for Alzheimer\u2019s Disease in relation to neuropathology and cognitive change. Acta Neuropathol 143:487\u2013503","journal-title":"Acta Neuropathol"},{"key":"13726_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23620-z","volume":"12","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ et al (2021) A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat Commun 12:3400","journal-title":"Nat Commun"},{"key":"13726_CR51","doi-asserted-by":"publisher","first-page":"356","DOI":"10.14283\/jpad.2023.34","volume":"10","author":"MS Rafii","year":"2023","unstructured":"Rafii MS (2023) Appropriate use recommendations for Lecanemab. J Prev Alzheimers Dis 10:356\u2013356","journal-title":"J Prev Alzheimers Dis"},{"key":"13726_CR52","unstructured":"Horie, K., et al. LB02-Plasma MTBR-Tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. in Clinical Trials in Alzheimer\u2019s Disease (CTAD) Congress, Vol. 20232023 S36 (2023)."},{"key":"13726_CR53","doi-asserted-by":"publisher","first-page":"108","DOI":"10.2967\/jnumed.120.254961","volume":"63","author":"A Gogola","year":"2022","unstructured":"Gogola A et al (2022) Direct comparison of the tau PET tracers (18)F-Flortaucipir and (18)F-MK-6240 in human subjects. J Nucl Med 63:108\u2013116","journal-title":"J Nucl Med"},{"key":"13726_CR54","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s43587-025-00835-z","volume":"5","author":"R Ossenkoppele","year":"2025","unstructured":"Ossenkoppele R et al (2025) Plasma p-tau217 and tau-PET predict future cognitive decline among cognitively unimpaired individuals: implications for clinical trials. Nat Aging 5:883\u2013896","journal-title":"Nat Aging"},{"key":"13726_CR55","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barth\u00e9lemy NR, He Y, Bateman RJ, Hansson O (2023) Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol 80:516\u2013522","journal-title":"JAMA Neurol"},{"key":"13726_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2021.118553","volume":"243","author":"CB Young","year":"2021","unstructured":"Young CB, Landau SM, Harrison TM, Poston KL, Mormino EC (2021) Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [(18)F]-AV-1451 PET data. Neuroimage 243:118553","journal-title":"Neuroimage"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13726-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13726-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13726-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T13:05:20Z","timestamp":1774530320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13726-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":56,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["13726"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13726-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from all ADNI participants, and ADNI received approval from the institutional review boards at all participating institutions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"183"}}